Drug · CHEMBL562

GRISEOFULVIN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. GRISEOFULVIN. Drugs and targets, record CHEMBL562. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL562

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: GRISEOFULVIN; ChEMBL
ChEMBL ID: CHEMBL562; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Fulcin, Fulcin 125, Fulcin 500, Fulsovin, Fulvicin p/g, Fulvicin p/g 165, Fulvicin p/g 330, Fulvicin-u/f, Grifulvin v, Gris-peg, Grisactin, Grisactin ultra, Griseofulvin, ultramicrosize, Griseofulvin,ultramicrosize, Grisol af, Grivate, Ultragris-165, Ultragris-330; ChEMBL
Other names: Grisactin v, Griseofulvin microsize, Griseofulvin permeability diameter, Griseofulvin, microcrystalline, Griseofulvin, microsize, Griseofulvin, ultramicrocrystalline, Griseofulvin, ultramicrosize, Griseofulvin,microsize, Griseofulvina, Griseofulvine, Griseofulvinum, NSC-34533, NSC-755822; ChEMBL
DrugBank: DB00400; DrugBank
InChIKey: DDUHZTYCFQRHIY-RBHXEPJQSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 4 diseases, from DailyMed; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases4

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
tinea pedis	Approval	DailyMed	4	1	https://conductscience.org/library/drugs?q=MONDO_0005984
candidiasis	Approval	DailyMed	3	0	https://conductscience.org/library/drugs?q=MONDO_0002026
tinea infection	Approval	DailyMed	3	0	https://conductscience.org/library/drugs?q=MONDO_0005982
infection	Approval	DailyMed	2	0	https://conductscience.org/library/drugs?q=EFO_0000544

Source Open Targets

Trials5

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT04318535	Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions	Phase 1	36	2020-12-28	griseofulvin	Its name	ClinicalTrials.gov
NCT00117767	Terbinafine Compared to Griseofulvin in Children With Tinea Capitis	Phase 3	720		griseofulvin	Its name	ClinicalTrials.gov
NCT01518166	Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH	Phase 1	70		griseofulvin	Its name	ClinicalTrials.gov
NCT00864071	A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions	Phase 1	50		griseofulvin	Its name	ClinicalTrials.gov
NCT00863863	A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions	Phase 1	40		griseofulvin	Its name	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
26426736	RESULT	1

Source PubMed

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL562

GET https://conductscience.org/api/drugs/v1/CHEMBL562/targets

API reference For AI assistants